Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

9.090 +0.350 (+4.00%)
Streaming Delayed Price Updated: 10:00 AM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Group: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Replimune Announces Pricing of Upsized Public Offering
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Proposed Public Offering
From Replimune Group Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views ↗
 
Via Benzinga
News headline image
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Dow Jumps 300 Points; Gap Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
News headline image
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025 ↗
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace
News headline image
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗
 
Via Benzinga
Topics Stocks
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
News headline image
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 ↗
REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Crude Oil Moves Lower; AutoZone Profit Tops Views ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Falls 100 Points; ISM Services PMI Increases In November ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.